JAGX Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.…
Industry Peers
BiotechnologyKey Statistics
About Jaguar Health (NASDAQ: JAGX)
›
Jaguar Health (NASDAQ: JAGX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 47 employees.
The shares were at 0.3270 USD on 19 November 2026, down 99.5% over 52 weeks. Its 52-week range is 0.2954 USD to 73.50 USD: the price is 99.6% below the high and 10.7% above the low.
Its market capitalisation is 4.36M USD.
Jaguar Health reports return on equity of 309.1%, an operating margin of -88.2% and revenue down 24.0% year over year.
It holds more cash than debt, a net cash position of 2.01M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.